Did you catch Veeva’s latest earnings report? Their fiscal Q2 2026 results are in, and they’re showing impressive growth! With significant advancements in AI and their Vault CRM solutions, Veeva is truly shaping the future of the life sciences industry. What impact do you think these innovations will have on healthcare?

Veeva Systems has delivered exceptional financial results for its fiscal second quarter of 2026, showcasing robust growth and strategic advancements across its comprehensive cloud solutions for the life sciences sector. The report highlights strong performance driven by customer success and innovative product development, setting a clear trajectory for continued leadership in the industry.

The company announced total revenues soaring to $789.1 million, marking a significant 17% increase year over year. Subscription services revenues also saw robust growth, reaching $659.2 million, an impressive 17% rise from the previous year. Furthermore, operating income surged by 18% and non-GAAP operating income by 26%, underscoring Veeva’s efficient operational management and strong financial growth.

CEO Peter Gassner expressed his enthusiasm, noting the exciting reality of Veeva’s vision for connected software, data, and business consulting in life sciences. He particularly highlighted the transformative potential of Veeva AI and Veeva Data Cloud, poised to revolutionize everything from clinical trials to commercial operations within the industry.

Echoing this positive sentiment, CFO Brian Van Wagener emphasized that Veeva delivered another strong quarter, surpassing all guidance metrics. He attributed this broad-based business strength to consistent execution and an unwavering focus on customer success, which are foundational to enabling durable, long-term expansion for the company.

A key area of innovation highlighted is Veeva’s deep, industry-specific Life Sciences AI. This initiative, incorporating agentic AI within the Vault Platform and specialized application agents across all Veeva applications, is advancing rapidly with a focused strategy aimed at delivering tangible customer value. Initial Veeva AI agents are slated for release in December for Vault CRM and commercial content, with further expansions into clinical operations, regulatory, safety, quality, medical, and other commercial areas planned through 2027.

Veeva also achieved significant milestones with its Vault CRM Suite. The platform is now operating at scale, introducing new capabilities including the planned December rollout of Veeva AI integration. Notably, two top 20 biopharmaceutical companies successfully deployed Vault CRM in major markets during the quarter, bringing the total number of live customers to over 100. Additionally, the seventh top 20 biopharma committed to Vault CRM as their commercial foundation in August, coinciding with the expansion of the suite to include Patient CRM, Campaign Manager, and Service Center.

Further cementing its position as the industry’s foundation for drug development and quality, Veeva reported that another top 20 biopharma selected Veeva eTMF, Study Startup, and Site Connect to modernize clinical operations. Two more top 20 biopharmas chose Veeva Submissions, Submissions Archive, and Registrations. This brings the count to all top 20 biopharmas utilizing Veeva eTMF, 19 with Veeva QualityDocs, and 18 with Veeva Submissions, demonstrating near-universal adoption of these critical cloud solutions.

In a strategic move, Veeva and IQVIA announced a long-term global partnership in August, successfully resolving all pending legal disputes. This collaboration is designed to simplify and streamline the use of joint Veeva and IQVIA products and services for shared customers across both commercial and clinical domains, promising enhanced synergy and efficiency for biopharma clients.

Looking ahead, Veeva provided optimistic guidance for its fiscal third quarter and the full fiscal year 2026, anticipating continued momentum and solid financial performance. The company remains dedicated to innovation and expanding its comprehensive suite of life sciences tools, reinforcing its commitment to empowering the global healthcare industry.